NEW YORK (GenomeWeb) – Researchers from the Massachusetts Institute of Technology this month reported new animal data showing that an endothelial cell-targeting nanoparticle can carry microRNAs and siRNAs into lung tumors and cause the cancer to regress.

The findings, which also show that the addition of chemotherapy to the small RNA treatment can further improve survival, point to the nanoparticle technology as yet another promising approach to overcoming the delivery challenge that has long hampered the development of nucleic acid medicines.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.